Brochure | April 14, 2022

NanoAssemblr® Blaze™: Power To Scale


A candidate drug must be shown to be both potent and non-toxic in relevant models. While early screening in murine models is enough to begin a program, the demands for data from larger models will increase.

Traditionally, process development for nanomedicine production at an intermediate scale is a barrier to this work. With NxGen™ technology on the NanoAssemblr® Blaze™, these important studies can be conducted efficiently with a process that mirrors a clinical scale implementation.

access the Brochure!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Cell & Gene